Literature DB >> 23280017

Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis.

S-F Wu1, J-W Zhang, W-Y Qian, Y-B Yang, Y Liu, Y Dong, Z-B Zhang, Y-P Zhu, Y-J Feng.   

Abstract

OBJECTIVE: To evaluate the expression of apoptosis-related genes and their correlation with prognosis in cervical cancer patients.
MATERIALS AND METHODS: The expressions of Survivin, Fas and FasL in tissues of cervical cancer, cervical intraepithelial neoplasia (CIN), chronic cervicitis and normal cervix wer detected by immunohistochemical staining, and the relationship between the expression of Survivin, Fas and FasL and clinical pathologic characteristics of cervical cancer was correlation analysis.
RESULTS: The positive expression rates of Survivin and FasL in cervical cancer tissues were significantly higher than those in tissues of normal cervix, chronic cervicitis and CIN (p < 0.05), but lower positive expression rate of Fas was observed in cervical cancer tissues when compared with that in normal cervix, chronic cervicitis and CIN tissues (p < 0.05). The expression of Survivin was significantly correlated with clinical staging and lymph node metastases of cervical cancer (p < 0.05). The expression of FasL was correlated with lymph node metastases, clinical staging and pathological grading of cervical cancer (p < 0.05). The expression of Survivin was negatively correlated with that of Fas (r = -0.517, p < 0.01), but positively correlated with that of FasL (r = 0.381, p < 0.01) in tissues of cervical cancer.
CONCLUSIONS: The up-regulated expression of Survivin and FasL and down-regulated expression of Fas may be involved in the carcinogenesis and development of cervical cancer. The expression of FasL may be one of the prediction indexes for disease progression and prognosis in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280017

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Clinicopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis.

Authors:  Yibing Fan; Juan Chen
Journal:  Bioengineered       Date:  2017-01-04       Impact factor: 3.269

2.  Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies.

Authors:  Lei Xu; Xin Zhou; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2013-10-05

3.  A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer.

Authors:  Mingmei Huangfu; Shuang Xu; Siyao Li; Baosheng Sun; Kuang-Hui Lee; Linlin Liu; Shilong Sun
Journal:  Tumour Biol       Date:  2016-01-06

4.  FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.

Authors:  Lei Xu; Xin Zhou; Feng Jiang; Man-Tang Qiu; Zhi Zhang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

Review 5.  The role of CD95 and CD95 ligand in cancer.

Authors:  M E Peter; A Hadji; A E Murmann; S Brockway; W Putzbach; A Pattanayak; P Ceppi
Journal:  Cell Death Differ       Date:  2015-02-06       Impact factor: 15.828

6.  Survivin Overexpression Is Associated with Aggressive Clinicopathological Features in Cervical Carcinoma: A Meta-Analysis.

Authors:  Ke-Yan Cheng; Zhi-Lian Wang; Qian-Yun Gu; Min Hao
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.